Drug
Efficacy
Physiostim offers a comprehensive approach to evaluating drug efficacy on cardiovascular endpoints using both ex vivo and in vivo models.
Thanks to our extensive expertise fully dedicated to cardiovascular area and with a senior scientist team we are proud to accelerate the development of your drug pipeline. Our knowledge, skills, and cutting-edge platform have successfully supported marketed therapeutic agents since 2001.
We’re proud to accelerate the development of your drug pipeline We’re fully accredited by AAALAC International. This recognition is the result of our commitment to ensuring ethical treatment of animals.
Evaluation of cardioprotective or cardiotoxicity effects with human cardiomyocytes (hiPSC-CMs)
In vitro hiPSC-CMs plateform for drugs in development
Development of new, more potent, and safer drugs requires an in vitro system where efficacy and safety can be tested. Human cardiomyocytes derived from induced pluripotent stem cells (hiPSC-CM) provide rapid, reproducible, and sensitive predictions of compounds' short-term and long-term pharmacological effects. Indeed, it is also an integrative system that could easily identify potential cardiotoxic effects of compounds (pro-arrhythmogenic, cytotoxic and contractility worsening). hiPSC-CM have contractile ability with ion channel activity and have been recognized for their potential in preclinical cardiotoxicity evaluation and drug discovery are relevant to anticipate drug-induced cardiac side effects.
Investigation of cardiac contractility (Ex-Vivo)
The Langendorff model is a robust model to investigate the effects on cardiac contractility in drug discovery investigations.
The Langendorff model is a robust model to investigate the effects on cardiac contractility in drug discovery investigations. We customize our isolated Langendorff heart studies to meet the needs of your project team and to integrate seamlessly into your drug development research. A template concentration range can be performed alone to investigate inotropy, chronotropy or both.
Evaluation of cardio protective effect on ischemia/reperfusion
The Langendorff model or Isolated Perfused Heart is a powerful tool to modelize ischemia/reperfusion injuries and investigate cardioprotective effect early in drug discovery.
A global ischemia induces a diastolic contracture (heart stunning) followed by a decrease of left ventricular function and incidence of ventricular arrhythmias, during reperfusion mimicking the clinical situation of human myocardial infarction. Therefore this model is relevant to evaluate cytoprotective agents against myocardial infarction damages.
Heart failure models (In-Vivo)
PhysioStim offers a wide range of in vivo heart failure models to assess the preclinical efficacy and in-depth functional characterization of pharmacological compounds under development.
To fullfil each clients needs we propose gold-standard or customized predictive-animal models.
Our heart failure models provide a broad assessment of cardiac function (echocardiographic analysis) and structure (histological staining of myocardial fibrosis) :
- Heart failure with preserved ejection fraction (HFpEF, angiotensin-II infusion and thoracic aorta constriction) Cardiotoxicity evaluation and inotropism
- Heart failure with reduced ejection fraction (HFrEF, permanent coronary artery ligation)
- Metabolic models of heart failure (high fat diet rats, db/db and ob/ob mice)
- Acute myocardial infarction (transient coronary artery ligation)
- Genetically-induced hypertension (SHR rats)
For heart failure models we offer a variety of discovery models delivering extensive assessment of cardiac function via echocardiography analysis and image analysis of cardiac fibrosis.
Myocardial infarction with reduced ejection fraction (HFrEF)
Main offerings
HIGH RESOLUTION
echocardiography
Quantitative
fibrosis scoring
Quantitative
whole heart imaging
Quantitative
plaque lesion imaging
Assessment of
plasma markers
Quantitative
electropharmacology